Skip to main content

Clinical Trials Using Tucatinib

Review the clinical trials studying tucatinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 33 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Status: Active
Location: 15 locations
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Status: Active
Location: 8 locations
A Study of Tucatinib and Trastuzumab in Patients with HER2-Positive Locally Advanced Rectal Cancer
Status: Active
Location: 7 locations
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Status: Active
Location: 5 locations
PRE-I-SPY Phase I/Ib Oncology Platform Program
Status: Active
Location: 7 locations
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Status: Active
Location: 6 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 4 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
Tucatinib Given Before Surgery to Patients with HER2 positive Cancers that have Spread to the Brain
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Tucatinib and T-DM1 for the Treatment of Patients with HER2-Positive Metastatic Solid Tumors and Brain Metastases, TUCATEMEB Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Status: Active
Location: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Status: Temporarily Closed to Accrual
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California